Compare · LFCR vs MRK
LFCR vs MRK
Side-by-side comparison of Lifecore Biomedical Inc. (LFCR) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LFCR and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $298.33B, about 1412.7x LFCR ($211.2M).
- Over the past year, LFCR is down 18.5% and MRK is up 50.7% - MRK leads by 69.2 points.
- MRK has been more active in the news (27 items in the past 4 weeks vs 12 for LFCR).
- MRK has more recent analyst coverage (25 ratings vs 6 for LFCR).
- Company
- Lifecore Biomedical Inc.
- Merck & Company Inc.
- Price
- $5.52-1.69%
- $119.49-1.15%
- Market cap
- $211.2M
- $298.33B
- 1M return
- +15.97%
- +6.40%
- 1Y return
- -18.46%
- +50.70%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 12
- 27
- Recent ratings
- 6
- 25
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest LFCR
- Director Kiper Christopher S was granted 25,907 shares (SEC Form 4)
- Director Obus Nelson was granted 25,907 shares, increasing direct ownership by 19% to 164,100 units (SEC Form 4)
- Director Aryeh Jason was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)
- Director Korenberg Matthew E was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)
- Director Schechter Joshua was granted 25,907 shares, increasing direct ownership by 24% to 133,080 units (SEC Form 4)
- Director Antunes Humberto Calheiros was granted 25,907 shares, increasing direct ownership by 55% to 72,967 units (SEC Form 4)
- Director Johnson Paul Harold was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)
- Director Houde Lovas Katrina was granted 25,907 shares, increasing direct ownership by 24% to 135,319 units (SEC Form 4)
- Lifecore Biomedical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer
Latest MRK
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
- SEC Form 4 filed by Director Warden Kathy J
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- SEC Form 4 filed by Director Thulin Inge G
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Russo Patricia F
- SEC Form 4 filed by Director Rothman Paul
- SEC Form 4 filed by Director Mayo Stephen